[Skip to Content]
[Skip to Content Landing]
Article
August 23, 1952

STATUS OF PRIMAQUINE: 1. MASS THERAPY OF SUBCLINICAL VIVAX MALARIA WITH PRIMAQUINE

Author Affiliations

Chicago; Army of the United States; United States Army

JAMA. 1952;149(17):1558-1562. doi:10.1001/jama.1952.72930340017010
Abstract

This report deals with the problem in mass therapy presented by the large number of cases of vivax malaria occurring in the United Nations forces in Korea since 1950.

Because malaria is not a single disease but instead is a complex of diseases all caused by a member of the genus plasmodium the unique properties of the members of the various species and strains of the organism must be considered in any given therapeutic problem.

On morphologic grounds, four distinct species of plasmodia are recognized. One species, Plasmodium ovale, is rare and of little clinical importance; two species, P. malariae and P. vivax, have many properties in common. For therapeutic purposes, they may be considered together. The remaining species, P. falciparum, has special properties and must be considered separately.

On physiologic grounds, each species is made up of several strains, each with idiosyncrasies that modify response to treatment. It is

×